Scott+Scott Attorneys at Law LLP Announces Investigation into Myriad Genetics, Inc. (MYGN)

NEW YORK, March 15, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN) or certain of its officers and directors violated federal securities laws. If you purchased Myriad securities on or after January 1, 2014, you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for more information.

Myriad is a molecular diagnostic company.

On March 12, 2018, Myriad disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. The subpoena requested that the Company produce documents relating primarily to the Company's billing to government-funded healthcare programs for the Company's hereditary cancer testing.

On this news, Myriad's share price fell $4.01 – over 12% – to close at $29.01 on March 13, 2018.

What You Can Do

If you purchased Myriad securities, and you wish to discuss this investigation, please contact attorney Rhiana Swartz at (844) 818-6980, or at [email protected].

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

CONTACT:

Rhiana Swartz
Scott+Scott Attorneys at Law LLP
230 Park Ave, 17^th Fl, NY, NY 10169
(844) 818-6980
[email protected] 

SOURCE Scott+Scott, Attorneys at Law, LLP

Related Links

http://scott-scott.com